Non-comparative, Opened Multicenter Study to Assess the Efficacy and Safety of ELIGARD 22.5mg in the Treatment of Subjects With Prostate Cancer
Phase of Trial: Phase IV
Latest Information Update: 16 Oct 2015
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors HanAll Biopharma
- 07 Jun 2017 Biomarkers information updated
- 22 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Mar 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.